Go to Patients & Caregivers Site

Prescribing Information

Co-pay cards through Nutropin GPS

The Nutropin Co-pay Card Program helps eligible patients with out-of-pocket expenses to help them access Nutropin.

Here’s how the co-pay assistance process works

Patients who are referred for co-pay assistance need not be enrolled in Nutropin GPS and can simply call 1-866-NUTROPIN (1-866-688-7674) for a referral. Co-pay assistance may be available for patients who are privately and publicly insured, including Medicare and state Medicaid patients.

Patients enrolled in Medicare Part D may be eligible to apply for co-pay assistance, including fees associated with true out-of-pocket expenses (TrOOP).

Key points to remember about co-pay referrals:

Genentech does not influence or control the operations of these independent, nonprofit organizations (INOs), but Nutropin GPS can assist patients to navigate the process of seeking co-pay assistance by making a referral that is appropriate based on a patient's diagnosis and by assisting with the application process.

We cannot guarantee co-pay assistance once a patient has been referred by Nutropin GPS. The INOs to which we refer patients have their own criteria with regard to patient eligibility, including financial eligibility.

Back to top

INDICATIONS

Pediatric Patients

Nutropin AQ® [somatropin (rDNA origin) injection] and Nutropin [somatropin (rDNA origin) for injection] are indicated for the long-term treatment of growth failure due to a lack of adequate endogenous GH secretion.

Nutropin AQ and Nutropin are also indicated for the treatment of growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Nutropin AQ and Nutropin therapy should be used in conjunction with optimal management of chronic renal insufficiency.

Nutropin AQ and Nutropin are also indicated for the long-term treatment of short stature associated with Turner syndrome.

Nutropin AQ and Nutropin are also indicated for the long-term treatment of idiopathic short stature, also called non-growth hormone deficient short stature, defined by height SDS ≤-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.

Adult Patients

Nutropin AQ and Nutropin are indicated for replacement of endogenous GH in adults with GH deficiency who meet either of the following two criteria:

  • Adult-Onset: Patients who have GH deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
  • Childhood-Onset: Patients who were GH deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.

In general, confirmation of the diagnosis of adult GH deficiency in both groups usually requires an appropriate GH stimulation test. However, confirmatory GH stimulation testing may not be required in patients with congenital/genetic GH deficiency or multiple pituitary hormone deficiencies due to organic disease.

IMPORTANT SAFETY INFORMATION

Contraindications

GROWTH HORMONE (GH) SHOULD NOT BE USED IN PATIENTS WITH:

  • Closed epiphyses for pediatric growth promotion
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Active malignancy
  • Acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma, or those with acute respiratory failure
  • Prader-Willi syndrome who are severely obese or have severe respiratory impairment. Nutropin AQ and Nutropin are not indicated in patients with Prader-Willi syndrome who do not also have a diagnosis of GH deficiency
  • Known sensitivity to benzyl alcohol when using Nutropin reconstituted with Bacteriostatic Water for Injection, USP (benzyl alcohol preserved). For use in newborns, see WARNINGS in full Prescribing Information

Additional Safety Information

  • Nutropin AQ and Nutropin should be prescribed by physicians experienced in the diagnosis and management of patients with pediatric or adult GH deficiency, Turner syndrome (TS), or chronic renal insufficiency (CRI).
  • Patients should be monitored for signs of glucose intolerance. Patients taking antihyperglycemic agents may require dose adjustment when GH therapy is instituted.
  • Patients with preexisting tumors or growth hormone deficiency secondary to an intracranial lesion should be examined routinely for progression or recurrence of the underlying disease process.
  • Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients treated with GH products.
  • In patients with hypopituitarism (multiple hormone deficiencies), standard hormonal replacement therapy should be monitored closely when GH therapy is administered.
  • Periodic thyroid function tests and thyroid replacement therapy should be initiated or appropriately adjusted when indicated.
  • Injection site discomfort has been reported.
  • Rotate injection site to avoid tissue atrophy that may result from subcutaneous administration of GH at the same site over a long period of time.
  • As with any protein, local or systemic allergic reactions may occur.

Pediatric Patients

  • Slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders or in patients undergoing rapid growth.
  • Children with growth failure secondary to CRI should be examined periodically for evidence of progression of renal osteodystrophy.
  • Progression of scoliosis can occur in patients who experience rapid growth. Patients with a history of scoliosis who are treated with GH should be monitored for progression of scoliosis.

Adult Patients

  • GH therapy may cause fluid retention.
  • Carpal tunnel syndrome, arthralgia, and other joint disorders have been reported in GH-treated patients.

Drug Interactions

  • Patients on GH therapy, with previously undiagnosed central (secondary) hypoadrenalism, may require glucocorticoid replacement therapy. Patients already on glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses.
  • Glucocorticoid replacement therapy should be carefully adjusted in children with concomitant GH and glucocorticoid deficiency to avoid both hypoadrenalism and an inhibitory effect on growth.
  • Careful monitoring is advisable when GH is given in any combination with agents metabolized by CP450 liver enzymes.
  • In women on oral estrogen replacement, a larger dose of somatropin may be required to achieve the defined treatment goal.

Please see full Prescribing Information for additional Important Safety Information.

The content available from this website is for informational purposes only. Individual results may vary. You may report side effects to the FDA at 1-800-FDA-1088 or to Genentech Drug Safety/Adverse Events at 1-888-835-2555.

Nutropin and Nutropin AQ are registered trademarks; and NuSpin, growingopportunity, and Nutropin GPS are trademarks of Genentech Inc.

Back to top



You can also speak to your dedicated case manager by calling:

1-866-NUTROPIN
(1-866-688-7674)

Important Safety Information

INDICATIONS

Pediatric Patients

Nutropin AQ® [somatropin (rDNA origin) injection] and Nutropin [somatropin (rDNA origin) for injection] are indicated for the long-term treatment of growth failure due to a lack of adequate endogenous GH secretion.

Nutropin AQ and Nutropin are also indicated for the treatment of growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Nutropin AQ and Nutropin therapy should be used in conjunction with optimal management of chronic renal insufficiency.

Nutropin AQ and Nutropin are also indicated for the long-term treatment of short stature associated with Turner syndrome.

Nutropin AQ and Nutropin are also indicated for the long-term treatment of idiopathic short stature, also called non-growth hormone deficient short stature, defined by height SDS ≤-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.

Adult Patients

Nutropin AQ and Nutropin are indicated for replacement of endogenous GH in adults with GH deficiency who meet either of the following two criteria:

  • Adult-Onset: Patients who have GH deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
  • Childhood-Onset: Patients who were GH deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.

In general, confirmation of the diagnosis of adult GH deficiency in both groups usually requires an appropriate GH stimulation test. However, confirmatory GH stimulation testing may not be required in patients with congenital/genetic GH deficiency or multiple pituitary hormone deficiencies due to organic disease.

IMPORTANT SAFETY INFORMATION

Contraindications

GROWTH HORMONE (GH) SHOULD NOT BE USED IN PATIENTS WITH:

  • Closed epiphyses for pediatric growth promotion
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Active malignancy
  • Acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma, or those with acute respiratory failure
  • Prader-Willi syndrome who are severely obese or have severe respiratory impairment. Nutropin AQ and Nutropin are not indicated in patients with Prader-Willi syndrome who do not also have a diagnosis of GH deficiency
  • Known sensitivity to benzyl alcohol when using Nutropin reconstituted with Bacteriostatic Water for Injection, USP (benzyl alcohol preserved). For use in newborns, see WARNINGS in full Prescribing Information

Additional Safety Information

  • Nutropin AQ and Nutropin should be prescribed by physicians experienced in the diagnosis and management of patients with pediatric or adult GH deficiency, Turner syndrome (TS), or chronic renal insufficiency (CRI).
  • Patients should be monitored for signs of glucose intolerance. Patients taking antihyperglycemic agents may require dose adjustment when GH therapy is instituted.
  • Patients with preexisting tumors or growth hormone deficiency secondary to an intracranial lesion should be examined routinely for progression or recurrence of the underlying disease process.
  • Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients treated with GH products.
  • In patients with hypopituitarism (multiple hormone deficiencies), standard hormonal replacement therapy should be monitored closely when GH therapy is administered.
  • Periodic thyroid function tests and thyroid replacement therapy should be initiated or appropriately adjusted when indicated.
  • Injection site discomfort has been reported.
  • Rotate injection site to avoid tissue atrophy that may result from subcutaneous administration of GH at the same site over a long period of time.
  • As with any protein, local or systemic allergic reactions may occur.

Pediatric Patients

  • Slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders or in patients undergoing rapid growth.
  • Children with growth failure secondary to CRI should be examined periodically for evidence of progression of renal osteodystrophy.
  • Progression of scoliosis can occur in patients who experience rapid growth. Patients with a history of scoliosis who are treated with GH should be monitored for progression of scoliosis.

Adult Patients

  • GH therapy may cause fluid retention.
  • Carpal tunnel syndrome, arthralgia, and other joint disorders have been reported in GH-treated patients.

Drug Interactions

  • Patients on GH therapy, with previously undiagnosed central (secondary) hypoadrenalism, may require glucocorticoid replacement therapy. Patients already on glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses.
  • Glucocorticoid replacement therapy should be carefully adjusted in children with concomitant GH and glucocorticoid deficiency to avoid both hypoadrenalism and an inhibitory effect on growth.
  • Careful monitoring is advisable when GH is given in any combination with agents metabolized by CP450 liver enzymes.
  • In women on oral estrogen replacement, a larger dose of somatropin may be required to achieve the defined treatment goal.

Please see full Prescribing Information for additional Important Safety Information.

View indication and safety information

INDICATIONS

Pediatric Patients

Nutropin AQ® [somatropin (rDNA origin) injection] and Nutropin [somatropin (rDNA origin) for injection] are indicated for the long-term treatment of growth failure due to a lack of adequate endogenous GH secretion.

Nutropin AQ and Nutropin are also indicated for the treatment of growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Nutropin AQ and Nutropin therapy should be used in conjunction with optimal management of chronic renal insufficiency.

Nutropin AQ and Nutropin are also indicated for the long-term treatment of short stature associated with Turner syndrome.

Nutropin AQ and Nutropin are also indicated for the long-term treatment of idiopathic short stature, also called non-growth hormone deficient short stature, defined by height SDS ≤-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.

Adult Patients

Nutropin AQ and Nutropin are indicated for replacement of endogenous GH in adults with GH deficiency who meet either of the following two criteria:

  • Adult-Onset: Patients who have GH deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
  • Childhood-Onset: Patients who were GH deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.

In general, confirmation of the diagnosis of adult GH deficiency in both groups usually requires an appropriate GH stimulation test. However, confirmatory GH stimulation testing may not be required in patients with congenital/genetic GH deficiency or multiple pituitary hormone deficiencies due to organic disease.

IMPORTANT SAFETY INFORMATION

Contraindications

GROWTH HORMONE (GH) SHOULD NOT BE USED IN PATIENTS WITH:

  • Closed epiphyses for pediatric growth promotion
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Active malignancy
  • Acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma, or those with acute respiratory failure
  • Prader-Willi syndrome who are severely obese or have severe respiratory impairment. Nutropin AQ and Nutropin are not indicated in patients with Prader-Willi syndrome who do not also have a diagnosis of GH deficiency
  • Known sensitivity to benzyl alcohol when using Nutropin reconstituted with Bacteriostatic Water for Injection, USP (benzyl alcohol preserved). For use in newborns, see WARNINGS in full Prescribing Information

Additional Safety Information

  • Nutropin AQ and Nutropin should be prescribed by physicians experienced in the diagnosis and management of patients with pediatric or adult GH deficiency, Turner syndrome (TS), or chronic renal insufficiency (CRI).
  • Patients should be monitored for signs of glucose intolerance. Patients taking antihyperglycemic agents may require dose adjustment when GH therapy is instituted.
  • Patients with preexisting tumors or growth hormone deficiency secondary to an intracranial lesion should be examined routinely for progression or recurrence of the underlying disease process.
  • Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients treated with GH products.
  • In patients with hypopituitarism (multiple hormone deficiencies), standard hormonal replacement therapy should be monitored closely when GH therapy is administered.
  • Periodic thyroid function tests and thyroid replacement therapy should be initiated or appropriately adjusted when indicated.
  • Injection site discomfort has been reported.
  • Rotate injection site to avoid tissue atrophy that may result from subcutaneous administration of GH at the same site over a long period of time.
  • As with any protein, local or systemic allergic reactions may occur.

Pediatric Patients

  • Slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders or in patients undergoing rapid growth.
  • Children with growth failure secondary to CRI should be examined periodically for evidence of progression of renal osteodystrophy.
  • Progression of scoliosis can occur in patients who experience rapid growth. Patients with a history of scoliosis who are treated with GH should be monitored for progression of scoliosis.

Adult Patients

  • GH therapy may cause fluid retention.
  • Carpal tunnel syndrome, arthralgia, and other joint disorders have been reported in GH-treated patients.

Drug Interactions

  • Patients on GH therapy, with previously undiagnosed central (secondary) hypoadrenalism, may require glucocorticoid replacement therapy. Patients already on glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses.
  • Glucocorticoid replacement therapy should be carefully adjusted in children with concomitant GH and glucocorticoid deficiency to avoid both hypoadrenalism and an inhibitory effect on growth.
  • Careful monitoring is advisable when GH is given in any combination with agents metabolized by CP450 liver enzymes.
  • In women on oral estrogen replacement, a larger dose of somatropin may be required to achieve the defined treatment goal.

Please see full Prescribing Information for additional Important Safety Information.

Scroll down to view complete indication and safety information

Close